natgillin/translations-raw huggingface dataset:
The intermediate polypeptides according to the formulae: wherein R is a carboxyl protecting group, preferably a C1-C4 alkyl or benzyl, Pe is an amino protecting group, and P4 is hydrogen or a hydroxyl protecting group. 
Međuprodukti polipeptidi prema formulama: [image] [image] gdje je R karboksilna zaštitna grupa, poželjno C1-C4 alkil ili benzil, Pɛ je amino zaštitna grupa i P4 predstavlja vodik ili hidroksilnu zaštitnu grupu.
The method of claim 1, wherein the TGEC is a reaction product of reacting nitric acid with a respective amino compound. 
Postupak prema patentnim zahtjevima 8 do 10, naznačen time, da TGEC jest produkt reakcije dušične kiseline s odnosnim amino spojem.
wherein the patient is an individual for whom the monotherapy with metformin is contraindicated and/or who has an intolerance against metformin at therapeutic doses; or wherein the patient is an individual with insufficient glycemic control despite monotherapy with a SGLT2 inhibitor; or wherein the patient is an individual with insufficient glycemic control despite monotherapy with a DPP IV inhibitor. 
17. Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac kod kojega je kontraindicirana monoterapija s metforminom i/ili koji nema toleranciju protiv metformina u terapeutskim dozama.
vii) a first formation index lower than a second formation index of the paper product devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition; and wherein the paper product further comprises a paper coating composition which comprises a functional coating for liquid packaging, barrier coatings, printed electronics applications, or a coating composition which comprises a co-processed microfibrillated cellulose and inorganic particulate material composition, optionally wherein the inorganic particulate is kaolin; 
prvi formacijski indeks manji od drugog formacijskog indeksa papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i gdje papirni proizvod dodatno sadrži mješavinu za oblaganje papira koja sadrži funkcionalnu oblogu za pakiranje za tekućine, obloge kao prepreke, aplikacije s otisnutom elektronikom, ili mješavinu za oblaganje koja sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala, gdje anorganski partikulirani materijal može biti kaolin; gdje mikrofibrilirana celuloza ima močivost vlakana od 20 do 50.
Use according to claim 6 or 7, wherein said composition is administered by pouring. 
Uporaba u skladu s patentnim zahtjevom 4, naznačena time, da se navedeni pripravak primjenjuje u i/ili oko rane.
24.The composition of item 1, wherein said composition contains fewer than about 1 contaminating parent bacterial cell per 108 minicells 
Pripravak prema zahtjevu 1, gdje taj pripravak sadrži manje od oko 1 kontaminirajuće roditeljske bakterijske stanice na 10? mini-stanica.
Examples of dementias are: AIDS dementia complex, Binswanger's disease, dementia with Lewy Bodies, frontotemporal dementia, multi-infarct dementia, Pick's disease, semantic dementia, senile dementia, and vascular dementia. 
- < demencija odabrana iz skupine koju čine: AIDS demencija kompleks, Binswangerova bolest, demencija s Lewy tjelešcima, frontotemporalna demencija, multiinfarktna demencija, Pickova bolest, semantička demencija, senilna demencija, apneja u snu u demenciji, te vaskularna demencija, ili
at least one pharmaceutically acceptable vehicle, 
najmanje jedan farmaceutski prikladan nosač;
A compound selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, da je spoj odabran iz skupine koju čine:
According to another preferred embodiment of the process according to the present invention, step d) is carried out in that both the ground calcium carbonate and/or the precipitated calcium carbonate of step b) and the hydrophobising agent of step c) are provided in the dry state or in a solvent. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se korak d) provodi tako da su oba prirodni kalcijev karbonat i/ili taložni kalcijev karbonat iz koraka b) i hidrofobirajuće sredstvo iz koraka c) osigurani u suhom stanju ili u otapalu.
The taps 55,56 are positioned elevated 57 in relation to the base 58 of the inner part, so that the taps may disengage said hole by pushing downwards on the release tap and thereby releasing the CD or DVD from the taps. 
Lamele 55, 56 su postavljene tako da su uzdignute u odnosu na bazu 58 unutarnjeg dijela, pa lamele mogu osloboditi navedeni otvor pritiskanjem prema dolje na lamelu za oslobađanje i pri tome se oslobađa CD ili DVD od lamela.
Also described is a method for antagonising the effects of oxytocin upon the oxytocin receptor, comprising administering to a patient in need thereof an antagonistic amount of a compound of formula (1). 
Također je opisan i postupak antagoniziranja učinaka oksitocina na oksitocinskom receptoru, koji se sastoji u primjeni na pacijentu kojem je to potrebno antagonističke količine spoja formule (1).
A composition according to claim 4 characterized in that the ratio of acetic acid to zeolite is from 7 to 35 % by weight, most preferably from 10 to 34 %, such as from 13 to 33 %. 
Pripravak prema zahtjevu 7, naznačen time što je omjer octene kiseline prema zeolitu od 7 to 35% težinski, najpoželjnije od 10 do 34%, kao što je od 13 do 33%.
Method of treating ceramic parts A, which is used in the industry of artificial synthetic fibers, for the purpose of recycling is divided into three main stages, namely: 
(54) Naziv izuma: POSTUPAK OBRADE KERAMIČKIH DIJELOVA, KOJI SE KORISTE U INDUSTRIJI UMJETNIH SINTETIČKIH VLAKANA, U SVRHU RECIKLIRANJA
Apparatus according to claim 2 wherein in the maintenance mode, the controller controls the third heat exchanger to substantially refrain from heating air inside the greenhouse. 
Uređaj prema bilo kojem od zahtjeva 2 ili 3, pri čemu u radnom režimu održavanja, kontrolor upravlja trećim izmjenjivačem topline tako da on u suštini ne zagrijava zrak unutar staklenika.
Subsequent rehydration of the alkene (II) will then give predominantly or exclusively a single enantiomer of the cis-dihydrotetrabenazine (VI). 
Rehidriranje alkena (II) neposredno nakon toga će dati predominantno ili potpuno pojedinačni enantiomer cis-dihidrotetrabenazina (VI).
In accordance with the invention, the new and improved process resides in the application to the exterior surface of post-harvest produce of an improved coating composition comprising an aqueous emulsion from 0.25 to 25 percent by weight polyvinylidene chloride copolymer, and from 0.0001 to 10 percent surfactant, preferably Triton-X. 
U skladu sa izumom, novi i poboljšani postupak predstavlja primjenu na vanjsku površinu ubranog proizvoda poboljšane smjese za oblaganje koja sadrži vodenu emulziju od 0.25 do 25 mas% poliviniliden klorid kopolimera, i od 0.0001 do 10 % površinski aktivnog sredstva, poželjno Triton-X.
sodium and/or magnesium lauryl ether sulphate (SLES) or isopropanolammonium lauryl ether sulphate, wherein n is equal to 1, in amount equal to 45% by weight; ii) silica in amount equal to 25% by weight; iii) a perfuming agent in amount equal to 3% by weight; 
natrij i/ili magnezij lauril eter sulfat (SLES) ili izopropanolamonijum lauril eter sulfat, pri čemu n je jednako 1, u količini jednako 45% po masi; ii) silicij dioksid u količini jednako 25% po masi; iii) agens za parfimiranje u količini jednako 3% po masi; iv) voda u količini jednako 23% po masi;
is hydrogen. 
Ra jest vodik.
Even more preferably, the polypeptide analog of the SP-C protein is represented by the general formula (Ic) (SEQ ID NO: 15): 
Pripravak rekonstituiranog surfakanta prema patentnom zahtjevu 7, naznačen time da je analog prirodnog surfakanta proteina SP-C predstavljen općom formulom (Ic)
The method according to Claim 1, wherein the organic chemical is at least one member selected from the group consisting of o-chlorophenol, p-chlorophenol, 2,4-dichlorophenol, p-tert-butylphenol, 1-naphthol, 3,5-xylenol, carbendazim, 17B-estradiol and bisphenol A. 
Postupak prema zahtjevu 1, naznačen time, da organska kemikalija je barem jedan član odabran iz skupine koja se sastoji od sljedećih: o-klorofenol, p-klorofenol, 2,4-diklorofenol, p-tert-butilfenol, 1-naftol, 3,5-ksilenol, karbendazim, 17fB-estradiol i bisfenol A.
Gin corresponds to the glucose concentration of the medium perfused into the system, expressed in grams per litre. 
Grm se odnosi na koncentraciju glukoze u hranjivoj podlozi koja struji kroz sustav, izražena u gramima po litri.
where alkyl is substituted by a substituent selected from the group consisting of hydroxy, methoxy and ethoxy, and represents hydrogen or R1 and R2 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, piperidine, azepane, piperazine, morpholine, thiomorpholine, 1-oxidothiomorpholine or 1,1-dioxidothiomorpholine, where azetidine, pyrrolidine, piperidine, azepane, piperazine, morpholine, thiomorpholine, 1-oxidothiomorpholine and 1,1-dioxidothiomorpholine may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy, trifluoromethyl, hydroxycarbonyl, C1-C3-alkyl, methoxy and methoxymethyl, 
R' predstavlja C>-C,-alkil, gdje alkil je supstituiran sa supstituentom odabranim iz skupine koju čine hidroksi, metoksi i etoksi, i R* predstavlja vodik, ili R' i R zajedno s dušikovim atomom na koji su oni vezani tvore azetidin, pirolidin, piperidin, azepan, piperazin, morfolin, tiomorfolin, 1-oksidotiomortfolin ili 1,1-dioksidotiomorfolin, gdje azetidin, pirolidin, piperidin, azepan, piperazin, morfolin, tiomorfolin, 1-oksidotiomorfolin i 1,1-dioksidotiomorfolin može biti supstituiran s 1 do 2 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži hidroksi, trifluorometil, hidroksikarbonil, Cy-C3-alk1l, metoksi i metoksimetil, ili
The aerosol forming substances can be in solid, semisolid, or liquid form. 
Supstanca za formiranje aerosola mogu biti u krutom, polukrutom ili tekućem obliku.
a single molecule DNA-targeting RNA or a nucleic acid encoding the single molecule DNA-targeting RNA, wherein the single molecule DNA-targeting RNA comprises in 5′ to 3′ order: a targeter-RNA that is capable of hybridizing with a target sequence of a target DNA, and 
RNK jednostruke molekule koja cilja na DNK, ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira navedenu RNK jednostruke molekule koja cilja na DNK, pri čemu RNK jednostruke molekule koja cilja na DNK, obuhvaća sljedeće:
A compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof for use in a method of treating an HCV infection in a patient. The compound for use according to claim 10 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 1 ili 2 koja dalje obuhvaća uporabu jednog ili dva dodatna spoja koji djeluju protiv HCV-a, prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili njegovom farmaceutski prikladnom soli ili sa spojem prema zahtjevu 2.
B is an immunogenic fragment of Pilin A (PilA) from Haemophilus influenzae, wherein the immunogenic fragment of PilA is at least 95% identical to amino acids 40-149 of SEQ ID NO. 58; 
B je imunogeni fragment PilA, najmanje 95% istovjetan aminokiselinama 40-149 iz bilo kojeg od SEQ ID NO. 58 do SEQ ID NO. 121;
Optionally five heat dissipating panels 226 (not shown in the figures) acting as secondary heat sink are mounted thereon the reverse side of fixtures 202 wherein the heat dissipating panel 226 is made of at least one thermally conductive material selected from the set of aluminum, iron, steel, copper or combinations or alloys thereof. 
826; 830; 926), koje je/su montirane na prednjoj ili stražnjoj strani rasvjetnog tijela (102), pri čemu su sekundarna hladila od najmanje jednog toplinski vodljivog materijala izrađena, koji je izabran između aluminija, željeza, čelika, bakra, ili njihovih kombinacija ili su odabrani među njihovim legiranjem dobivenih legura.
Trans-isomeric compounds are described in more detail in our concurrently filed patent application (EP-A 80303810.8), entitled "Antidepressant Derivatives of Trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine". 
Trans-izomerni spojevi opisani su detaljnije u našoj konkurentno -podnijetoj patentnoj prijavi, pod naslovom "Antidepresantni derivati trans-4-fenil-1,2,3,4-tetrahidro-1-naftalinamina",
is in para position. Compounds of the formula I as claimed in claims 1 to 15 in which 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 15, gdje R7 je Hili F.
Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. 
Iskusni u struci razumiju također da striktnost uvjeta ovisi i o duljini sljedova DNA, oligonukleotidnih proba (poput 10-40 baza) ili miješanih oligonukleotidnih proba.
Most Preferred Groups of Synonymous Amino Acids 
Najpoželjnije Skupine Sinonimnih Aminokiselina
[SEQ ID NO: 29] GKGLEWLSYISGGSSYIFYADSVRGR Also preferred is that the antibody, fragment, variant, fusion or derivative comprises a variable heavy chain (VH) in which CDR3 comprises or consists of the amino acid sequence of: 
GKGLEWLSYISGGSSYIFYADSVRGR [SEQ ID NQ:29] pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDR3 sadrži ili se sastoji od sekvence amino kiselina:
Blend in the soft butter and oil to make a soft dough. 
Izmiješati maslac i ulje, da se dobije glatko tijesto.
The method of item 3, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, carboxymethyl cellulose, carboxymethylcellulose calcium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, low substituted hydroxypropylcellulose, and hydroxypropyl starch. 
Postupak prema zahtjevu 3, naznačen time što je sredstvo za raspadanje odabrano iz skupine koju čine natrijev škrob glikolat, karboksimetilceluloza, kalcijeva karboksimetilceluloza, natrijev karboksimetil škrob, natrijeva kroskarmeloza, krospovidon, nisko supstituirana hidroksipropilceluloza, i hidroksipropil škrob.
substitution at nucleotide position 2889 to G. 
supstituciju na mjestu nukleotida 2889 u G. 4.
As the aforementioned dose examples are only to be understood as dose examples per single application (i. e. per puff) multiple application of the combinations according to the invention leads to multiple doses of the aforementioned examples. 
Kako gore navedene primjere doza treba smatrati isključivo primjerima doze za pojedinačnu primjenu (tj. po udisaju), višestruka primjena kombinacija sukladno predmetnom izumu vodi do višestrukih doza gore navedenih primjera.
Apparatus (1) according to any one of claims 5 to 9, characterised in that the apparatus (1) includes a buffer system (8) that contains a number of rollers for equalization of traction in the rolled-up in mould labels. 
Uređaj (1) u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što uređaj (1) ima sustav odbojnika (8), koji sadrži više valjaka za ujednačavanje vlačne sile kod valjanih spljoštenih objekata.
Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or 
Prsten A je opciono supstituirani benzenov prsten, i Prsten B je opciono supstituirani nezasićeni monociklično heterociklični prsten, ili opciono supstituirani nezasićeni fuzirani heterobiciklični prsten, pri čemu je Y povezan za heterociklični prsten fuziranog heterobicikličnog prstena; ili
A compound of formula or a tautomer, N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein 
Spoj formule ili njegov tautomer, N-oksid, farmaceutski prihvatljiv ester ili njegova farmaceutski prihvatljiva sol, naznačeno time, što prsten Hy predstavlja po izboru supstituiran s R'";
In certain embodiments, the opioid analgesic of the present invention is selected from the group consisting of oxycodone, hydromorphone, hydrocodone, codeine, morphine, buprenorphine, pharmaceutically acceptable salts thereof, and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je opioidni analgetik odabran iz skupine koja se sastoji od oksikodona, hidromorfona, hidrokodona, kodeina, morfina, buprenorfina, njihovih farmaceutski prihvatljivih soli i njihovih smjesa.
is halogen, cyano or C1-3alkyl, n is 2, wherein R1 can be identical or different; 
R! je halogen, cijano ili C,salkil, n je 2, gdje R' može biti identičan ili različit;
Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1, With the exclusion of the following compound: 
Yi Y2 Ary, An, Ri, R2, 1, j, Kk, 1 su kao što je definirano u patentnom zahtjevu 1, sa izuzetkom sljedećeg spoja:
A highly concentrated, stable pharmaceutical anti-HER2 antibody formulation according to any one of claims 1 to 7, wherein the stabilizer is at a concentration of 15 to 250 mM or about 210 mM, respectively. 
Visoko koncentrirana, stabilna farmaceutska formulacija protutijela anti-HER2 prema bilo kojem zahtjevu od 1 do 7, naznačena time, da stabilizator je u koncentraciji od 15 do 250 mM ili oko 210 mM.
a light chain variable region (LCVR) including the amino acid sequence of SEQ ID NO:12. 
slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:4 ili 8.
is a reaction product of diisobutylene and diphenylamine; 
(b) je produkt reakcije diizobutilena i difenilamina;
Methods: Three different animal models of epilepsy (generalized non convulsive, generalized tonic-clonic and temporal lobe seizures) have been used, as described below: 
Metode: Korištena su tri različita životinjska modela epilepsije (opća nekonvulzivna i opća toničko-klonička i napadi temporalnog režnja), kako je dolje opisano: 1.
to 40 Muitiparticulates according to claim 11, wherein the percentage amounts of the ingredients (a) to (e) are as given in the following table, based on the total weight of the five ingredients: 
Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su postotne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na temelju ukupne težine pet sastojaka:
is a hydrogen atom, a lower alkyl group optionally substituted by one or more halogen atoms, a cycloalkyl group, a cycloalkylcarbonyl group, a lower alkanoyl group optionally substituted by one or more halogen atoms, a lower alkenyl group, an amino substituted lower alkanoyl group optionally substituted by one or more lower alkyl groups, or a lower alkylsulfonyl group; 
R" je atom vodika, C,4 alkil skupina opcijski supstituirana s jednim ili više halogen atoma, cikloalkil skupina, cikloalkilkarbonil skupina, C;4 alkanoil skupina opcijski supstituirana s jednim ili više halogen atoma, C24 alkenil skupina, amino supstituirana C;.4 alkanoil skupina opcijski supstituirana s jednom ili više C, 4 alkil skupina, ili Cig alkilsulfonil skupina;
The method according to item 20, wherein said skin is exposed to actinic light for a period of about 60 seconds to about 5 minutes per cm2 of an area to be treated. 
Kompozicija za primjenu prema patentnom zahtjevu 8, gdje je navedeno vrijeme tretmana oko 60 sekundi do oko 5 minuta po cm" područja koja treba tretirati.
The use according to aspect 22, wherein the self-binding pigment particle suspension is used in wet end process of a paper machine, in cigarette paper and/or coating applications, or as a support for rotogravure and/or offset and/or digital printing. 
Uporaba prema zahtjevu 22, gdje se suspenzija samoljepljivih pigmentnih čestica koristi u procesu vlažnog kraja papirnog stroja, za cigaretni papir i/ili primjene u oblaganju, ili kao potpora za rotogravuru i/ili offset i/ili digitalni tisak.
Since then, other ligands than IDA were used to chelate metal ions to resins. 
Danas se koriste drugi Ugandi za heliranje metanih iona kao nosače.
T and U are independently a nitrogen atom or a methine group, provided that the compounds wherein R1 is a methyl group and R2 is an unsubstituted phenyl group are excluded, or a salt or ester thereof. 
niža alkinil skupina je linearna ili razgranata alkinil skupina s 2 do 6 atoma ugljika i ciklo-niža alkil skupina je cikloalkil skupina s 3 do 6 atoma ugljika; uz uvjet da su isključeni spojevi gdje je R1 metil skupina i R2 je nesupstituirana fenil skupina, ili njegova sol ili ester.
The feed stock described herein comprises at least one component of processed municipal solid waste, a sorbent, and optionally other components. 
Modificirano zamjensko gorivo, koje sadržava najmanje jednu komponentu koja je dobivena iz procesiranog komunalnog otpada, a sirovina sadržava:
The liquefied gas treatment system according to claim 2, wherein a liquid component of the BOG, which is decompressed to a gas-liquid mixed state while passing through the decompressing means, is returned to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se tekuću komponentu BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), vraća u spremnik za teret (1;11)
Where present, the thiazolidinedione anti-diabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day. 
Gdje je prisutno, tiazolidinedionsko anti-dijabetično sredstvo se može koristiti u količinama unutar opsega od oko 0.01 do oko 2000 mg/dan koja se može primjenjivati u jednoj ili podijeljenim dozama jedan do četiri puta na dan.
Forage 8 would then be more in a form that is lying on the conveyor. 
Krupna stočna hrana & tada više naliježe na transporter.
The topical veterinary composition of claim 13, wherein the at least second active agent is a milbemycin, and wherein the milbemycin is moxidectin or milbemycin oxime. 
Topikalni veterinarski pripravak prema zahtjevu 8, naznačen time, da avermektin ili milbemicin je eprinomektin, ivermektin, selamektin, milbemektin, milbemicin D, milbemicin oksim ili moksidektin.
The process of claim 8, wherein the batch is acceptable for inclusion in the pharmaceutical composition only if its percentage of brominated tyrosine so measured is less than 0.2%. 
Postupak prema patentnom zahtjevu 8, naznačen time, da je šarža prihvatljiva za uključivanje u farmaceutski sastav samo onda, kada je njen postotak tako izmjerenog bromiranog tirozina manji od 0,2%.
The shoe (200) according to claim 2, characterized in that said inshoe (227) is provided separately and is coupled hermetically to said assembly (212) by gluing. 
Cipela (200) sukladno patentnom zahtjevu 8, naznačena time, da je navedena unutarnja cipela (227) izvedena odvojeno i lijepljenjem hermetički spojena s navedenim sklopom (212).
drying the obtained rifaximin precipitate at a temperature ranging from room temperature to 40° C. under a pressure comprised between ambient pressure and under vacuum, for a duration of time ranging from 5 minutes to 1 day, wherein the precipitate before drying is optionally washed with an apolar solvent. 
sušenja dobivenog taloga na temperaturi u rasponu od sobne temperature do 40 *C pod tlakom koji se kreće između tlaka okoliša i vakuuma, u trajanju u rasponu od 5 minuta do 1 dan, gdje se talog prije sušenja može isprati nepolarnim otapalom.
The compound of claim 5, which is: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 
Tvar za uporabu u skladu s patentnim zahtjevom 4, koja je: [image] [image] ili njena farmaceutski prihvatljiva sol, solvat ili njen stereoizomer. [image]